Ron Pfeifer Immunity Pharma BoardRon Pfeifer

Mr. Pfeifer is a seed investor in Immunity Pharma and the chair of the Board of Directors. Mr. Pfeifer is a real estate entrepreneur and investor, involved in three American companies. A serial investor since 1999, he invests in dozens of young companies focused on early stage and diversified new markets. His investments include biopharma and medical device, greentech and fintech, defence and security as well as automotive. Mr. Pfeifer invested in the first round of Mobileye. In addition to his role at Immunity Pharma, Mr. Pfeifer serves in the board of directors of three other companies.
Mr. Pfeifer holds a B.Sc. degree in Physical Geography and a management degree, both from the Hebrew University of Jerusalem.

Oren Becker Immunity Pharma BoardOren M. Becker, Ph.D.

Dr. Becker is a co-Founder and member of the Board of Directors of Immunity Pharma. He brings more than 20 years of biopharmaceutical industry and leadership experience, as a serial entrepreneur with expertise in the discovery and development of innovative pharmaceuticals. Dr. Becker is a co-Founder and founding President of R&D for Upstream Bio (Waltham, MA). Formerly he was the President and CEO of Vidac Pharmaceuticals; Founder and CEO of Dynamix Pharmaceuticals; and Founder and CSO of Epix Pharmaceuticals (NASDAQ:EPIX; formerly Predix Pharma). Dr. Becker led or co-led more than $2B worth deals with various pharma companies. He led the discovery and clinical development of 9 drug candidates across oncology, neurology, and inflammatory indications. Prior to that Dr. Becker was a professor at Tel-Aviv University and a visiting professor at Harvard University. He holds a Ph.D. from the Hebrew University of Jerusalem, and a postdoc from Harvard University. Dr. Becker has published more than 50 scientific papers, co-edited two books, and is an inventor of more than 30 patents.

Brian Schwartz Immunity Pharma BoardBrian Schwartz, MD

Dr. Schwartz has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries primarily in oncology, hematology, and rare diseases. During the past decade he has served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7bn by Merck & Co. in 2020. Prior to ArQule, Dr. Schwartz was CMO at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma. He is currently a Board Member of Mereo Biopharma, Enlivex, Cyclacel Pharmaceuticals and Infinity Pharmaceuticals. In addition, he serves as an advisor, SAB member and independent consultant for numerous biotech and investment companies. He received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior to his career in the biopharmaceutical industry.

Gideon Stein Immunity Pharma BoardGideon Stein, Ph.D.

Dr. Gideon Stein has been at Mobileye since its beginning in May 1999. He was first VP R&D at Mobileye Vision Technologies Ltd and he is currently the Chief Research Scientist at Mobileye, an Intel Company. He is also a serial investor in Israeli start-ups. Dr. Stein received his B.Sc. from the Technion, Haifa and his M.Sc. and Ph.D. from MIT both in the field of computer vision. He is an inventor on over 150 granted and pending patents.

Eran Ovadia Immunity Pharma BoardEran Ovadia

Eran Ovadia has been a high-tech manager since 1992. He directed strategic new product development activities in ServiceSoft and Comverse Network Systems. Since 2004 he has led entrepreneurial activities in the areas of biotechnology that ultimately led him to founding the drug development company Immunity Pharma Ltd, based on technologies from the Weizmann Institute of Science. Eran has an MBA degree (Tel Aviv International School of Management) and life science degree (The Hebrew University of Jerusalem).